Import Safety Rules Should Not Hinder Legitimate Generic Drug Markets: The Anti-Counterfeiting Trade Agreement (ACTA)
IMPORT SAFETY: REGULATORY GOVERNANCE IN THE GLOBAL ECONOMY, Cary Coglianese, Adam Finkel, David Zaring, eds., The University of Pennsylvania Press, 2009
30 Pages Posted: 25 May 2009 Last revised: 30 Jul 2014
Date Written: 2009
Trade agreement negotiations are routinely cloaked in secrecy, a model that may have suited the Eighteenth Century, but has no place in modern democracies. Transparency deficits have led to capture by powerful industries, sometimes to the detriment of public health. This is a standard account of the WTO TRIPS Agreement, but the pattern is being repeated, in a new regime, in the Anti-Counterfeiting Trade Agreement (ACTA) and related efforts. In the context of pharmaceuticals, ACTA should be limited to deliberate trademark violations and should not be expanded to encompass other intellectual property rights such as patent infringement. Recent seizures of generic medicines by Dutch authorities highlight the danger to legitimate and valuable global generic drug markets from overzealous enforcement of border control regimes.
Keywords: counterfeit, drug, pharmaceutical, Anti-Counterfeit Trade Agreement, ACTA, IMPACT
JEL Classification: K11, K23, K33
Suggested Citation: Suggested Citation